24 "Urinary Bladder" clinical trials found.
-
A Phase 1 Open-Label Study of the Safety Tolerability and Efficacy of KPT-9274 A Dual Inhibitor of PAK4 and NAMPT in Patients with Advanced Solid Malignancies or Non-Hodgkin's Lymphoma (PANAMA)
if you are newly diagnosed with non-Hodgkin's lymphoma or advanced solid malignancies, you may qualify to participate in a clinical trial. The main goal ...
-
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy
In this study, participants with high risk non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette Guerin (BCG) therapy and who are considered ineligible for ...
-
A Randomized Phase II Trial of Atezolizumab with or without Bevacizumab in Cisplatin-ineligible Patients with Advanced/Unresectable Urothelial Cancer
If you have been diagnosed with urothelial or transitional cell cancer that cannot be operated on or has spread and you are not a candidate ...
-
A Phase I Open Label Study of GSK3359609 Administered alone in Combination with Anticancer Agents in Subjects with Selected Advanced Solid Tumors
If you have been diagnosed with selected advanced or recurrent solid tumors including bladder cancer, cervical cancer, colorectal cancer, esophageal cancer with squamous cell ...
-
A PHASE 1B OPEN-LABEL MULTICENTER STUDY TO INVESTIGATE THE SAFETY AND PRELIMINARY EFFICACY OF NKTR 214 IN COMBINATION WITH ANTI-PD-1 (PEMBROLIZUMAB) FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC MELANOMA LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER OR METASTATIC NON-S ALL CELL LUNG CANCER
If you have been diagnosed with locally advanced or metastatic (the spread of) melanoma, locally advanced or metastatic (the spread of) urothelial bladder cancer or ...
-
A Phase II Open Label Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1 / PD-L1 Based Immunotherapy
If you have been diagnosed with urothelial cancer that has progressed or returned, you may be qualified for this Phase 2 study. The main goal ...
-
PHASE III RANDOMIZED ADJUVANT STUDY OF MK-3475 (PEMBROLIZUMAB) IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA (AMBASSADOR) VERSUS OBSERVATION
The purpose of this study is to compare any good and bad effects of using a drug called MK-3475 (pembrolizumab) after the removal of your ...
-
A phase I open-label dose-escalation study to investigate the safety pharmacokinetics pharmacodynamics and clinical activity of GSK3368715 in participants with solid tumors and DLBCL
The purpose of this study is to test the safety, tolerability, and effectiveness of GSK3368715 (called the study drug from now on) for solid tumors ...
-
Afatinib in advanced refractory urothelial cancer
If you have been diagnosed with urothelial cancer (a type of bladder cancer), which cannot be removed surgically at this time and has grown after ...
-
A Phase 2 Open-label Multicenter Study of an Immunotherapeutic Treatment DPX-Survivac in combination with Low Dose Cyclophosphamide and Pembrolizumab in Subjects with Selected Advanced and Recurrent Solid Tumours.
In this study, we are trying to determine the safety and ability of an investigational product, called DPX Survivac, to help the immune system fight ...
